51. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy
- Author
-
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, and Amy Jennings
- Subjects
Anti-HIV Agents ,Retrovirology and HIV immunopathogenesis ,Integrase inhibitor ,lcsh:Medicine ,Genomics ,HIV Infections ,Viral diseases ,Biology ,Biostatistics ,Microbiology ,DNA sequencing ,Deep sequencing ,Raltegravir Potassium ,Virology ,Drug Resistance, Viral ,medicine ,Humans ,Treatment Failure ,Genome Sequencing ,lcsh:Science ,Illumina dye sequencing ,Multidisciplinary ,lcsh:R ,Statistics ,High-Throughput Nucleotide Sequencing ,Computational Biology ,HIV ,HIV diagnosis and management ,Raltegravir ,Antivirals ,Pyrrolidinones ,3. Good health ,Mutation ,HIV-1 ,Pyrosequencing ,Medicine ,Infectious diseases ,lcsh:Q ,Sequence Analysis ,Mathematics ,medicine.drug ,Research Article - Abstract
Background The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 raltegravir-resistant MVs. Methods A5262 was a single-arm study of raltegravir and darunavir/ritonavir in treatment-naive patients. Pre-treatment plasma was obtained from 5 participants with raltegravir resistance at the time of virologic failure. A control library was created by pooling integrase clones at predefined proportions. Multiplexed sequencing was performed with Illumina and 454 platforms at comparable costs. Illumina sequence analysis was performed with the novel snp-assess tool and 454 sequencing was analyzed with V-Phaser. Results Illumina sequencing resulted in significantly higher sequence coverage and a 0.095% limit of detection. Illumina accurately detected all MVs in the control library at ≥0.5% and 7/10 MVs expected at 0.1%. 454 sequencing failed to detect any MVs at 0.1% with 5 false positive calls. For MVs detected in the patient samples by both 454 and Illumina, the correlation in the detected variant frequencies was high (R2 = 0.92, P
- Published
- 2013